The FDA has approved AbbVie/Johnson & Johnson's Imbruvica in combination with Roche's Gazyva in treatment-naïve patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL).Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.